16 completed, 4 unknown, 2 recruiting, 1 terminated. 8 Phase 2, 7 Phase 3, 5 Phase 1, 3 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 6, Recruiting 1, Terminated 1 |
| Phase 3 | 7 | Completed 3, Unknown 2, Recruiting 1, Terminated 1 |
| Phase 1 | 5 | Completed 3, Unknown 2 |
| Phase 4 | 3 | Completed 3 |
Follow Laboratorio Elea Phoenix S.A.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Trial with Cannabidiol (Kanbis®) for Parkinson Disease Symptoms Cannabidiol 100 mg/ml, cannabidiol 300 mg/ml, Cannabidiol 400 mg/ml - Parkinson Disease | Phase 2 | Recruiting | Laboratorio Elea Phoenix S.A. | 88 | 2024-11-28 | 2024-12-05 |
| Double-blind Study to Evaluate the PK, Efficacy, Safety and Immunogenicity of MB12 Versus Keytruda® in Stage IV NSCLC Pembrolizumab, Pembrolizumab biosimilar - Non Small Cell Lung Cancer Metastatic | Phase 3 | Unknown | Laboratorio Elea Phoenix S.A. | 174 | 2023-08-15 | 2024-07-16 |
| Shorter Benznidazole Regimens Compared to the Standard Regimen for Chagas Disease Short regimen of benznidazole, Short treatment with benznidazole, Standard treatment with benznidazole - Chagas Disease | Phase 3 | Recruiting | Laboratorio Elea Phoenix S.A. | 300 | 2021-07-28 | 2023-11-30 |
| Effectiveness and Safety Study of Specific Hyperimmune Equine Serum for the Treatment of Severe Hospitalized SARS-CoV-2 in Adults: Retrospective Cohort Study Covid19 | Completed | Inmunova S.A. | 847 | 2021-05-22 | 2022-04-06 | |
| Clinical Trial to Evaluate the Efficacy, Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (COVID-19) Inactivated SARS-CoV-2 vaccine (Vero cell), Placebo/Aluminum Adjuvant of Inactivated SARS-CoV-2 vaccine - COVID-19 Virus Infection | Phase 3 | Completed | Laboratorio Elea Phoenix S.A. | 3000 | 2020-09-16 | 2022-01-12 |
| Telmisartan for Treatment of COVID-19 Patients Telmisartan arm will receive 80 mg Telmisartan twice daily plus standard care. - COVID-19 Drug Treatment | Phase 4 | Completed | Laboratorio Elea Phoenix S.A. | 400 | 2020-05-19 | 2020-12-24 |
| Ivermectin Effect on SARS-CoV-2 Replication in Patients With COVID-19 IVERMECTIN (IVER P®) arm will receive IVM 600 µg / kg once daily plus standard care. CONTROL arm will receive standard care. - COVID-19 Drug Treatment | Phase 2 | Completed | Laboratorio Elea Phoenix S.A. | 45 | 2020-05-18 | 2020-10-05 |
| Bioequivalence Study of Two Extended Release Formulations Containing 50 mg of Quetiapine. Quetiapine - Healthy | Phase 4 | Completed | Laboratorio Elea Phoenix S.A. | 24 | 2017-03-13 | 2017-10-23 |
| Safety and Clinical Effectiveness of Intravitreal Bevacizumab (Lumiere®) in Patients With Wet Age-related Macular Degeneration (Wet AMD) Bevacizumab (Lumiere®) - Age-Related Macular Degeneration | Phase 3 | Completed | Laboratorio Elea Phoenix S.A. | 22 | 2017-02-07 | 2020-10-28 |
| Racotumomab in Patients With High-risk Neuroblastoma Racotumomab - Neuroblastoma | Phase 2 | Completed | Laboratorio Elea Phoenix S.A. | 39 | 2016-11-01 | 2023-09-11 |
| Bioequivalence Study of Two Formulatiosns With the Asscociaton of Efavirenz, Emtricitabine and Tenofovir Efavirenz, tenofovir disoproxil fumarate and emtricitabine - Healthy | Phase 4 | Completed | Laboratorio Elea Phoenix S.A. | 24 | 2016-09-04 | 2017-10-13 |
| Bioequivalence Study Bevacizumab Biosimilar (BEVZ92) Versus Bevacizumab (AVASTIN®) in First-line Treatment mCRC Patients Bevacizumab biosimilar (BEVZ92), Avastin® (bevacizumab, reference product) - Metastatic Colorectal Cancer (mCRC) | Phase 1 | Completed | mAbxience Research S.L. | 142 | 2014-10-29 | 2019-07-23 |
| Bioequivalence Study of Two Formulations With the Association of Tenofovir 300 mg and Emtricitabine 200 mg. Tenofovir disoproxil fumarate and emtricitabine - Acquired Immunodeficiency Syndrome | Phase 1 | Completed | Laboratorio Elea Phoenix S.A. | 24 | 2014-09-01 | 2015-10-22 |
| Study of RTXM83 Plus CHOP Chemotherapy Versus a Rituximab Plus CHOP Therapy in Patients With Non Hodgkin's Lymphoma RTXM83, Mabthera - Diffuse Large B-cell Lymphoma | Phase 3 | Completed | mAbxience Research S.L. | 272 | 2013-05-01 | 2019-09-26 |
| Desmopressin (DDAVP) in Patients With Colorectal Cancer and Rectal Bleeding Desmopressin - Colorectal Cancer, Rectal Bleeding | Phase 2 | Completed | Laboratorio Elea Phoenix S.A. | 30 | 2013-04-01 | 2017-08-24 |
| Perioperative Use of Desmopressin (DDAVP) in Breast Cancer Desmopressin - Breast Cancer | Phase 2 | Completed | Laboratorio Elea Phoenix S.A. | 21 | 2011-11-01 | 2015-08-28 |
| Concurrent Treatment of Squamous Cell Carcinoma or Adenocarcinoma of the Cervix With CIGB-300 for Local Application CIGB300 - Squamous Cell Carcinoma of the Cervix, Adenocarcinoma of the Cervix | Phase 2 | Completed | Laboratorio Elea Phoenix S.A. | 18 | 2011-05-01 | 2016-08-02 |
| Use of Racotumomab in Patients With Pediatric Tumors Expressing N-glycolylated Gangliosides racotumomab - Neuroblastoma, Ewing's Sarcoma | Phase 1 | Completed | Laboratorio Elea Phoenix S.A. | 15 | 2011-02-01 | 2015-07-29 |
| Single Dose Bioequivalence Study of Darifenacin Tablets 7.5 mg in Fed Healthy Volunteers. Darifenacin - Bioequivalency | Phase 1 | Unknown | Center for Clinical Pharmacology Research Bdbeq S.A. | 24 | 2010-12-01 | 2010-10-27 |
| Single Dose Two-periods Crossover Bioequivalence Study of Darifenacin Tablets in Healthy Volunteers. Darifenacin - Bioequivalency | Phase 1 | Unknown | Center for Clinical Pharmacology Research Bdbeq S.A. | 24 | 2010-11-01 | 2010-10-25 |
Showing 20 of 23. Sign in to see all of them.
COVID-19 (4) · Colorectal Neoplasms (2) · Neuroblastoma (2) · Small Cell Lung Carcinoma (2) · Acquired Immunodeficiency Syndrome (1) · Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Chagas Disease (1) · Condylomata Acuminata (1) · Gastrointestinal Hemorrhage (1) · Glioma (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Non-Hodgkin (1) · Macular Degeneration (1) · Marijuana Abuse (1)
racotumomab (4) · Bevacizumab (2) · Cholinergic Agents (2) · Cholinergic Antagonists (2) · Deamino Arginine Vasopressin (2) · Emtricitabine (2) · Muscarinic Antagonists (2) · Tenofovir (2) · darifenacin (2) · BEVZ92 (1) · CIGB-300 (1) · Cannabidiol (1) · Fluorouracil (1) · Irinotecan (1) · Ivermectin (1)
Argentina (21) · Brazil (3) · India (2) · Indonesia (2) · Philippines (2) · Uruguay (2) · Colombia (1) · Cuba (1) · Iran (1) · Malaysia (1) · Mexico (1) · Paraguay (1) · Russia (1) · Singapore (1) · South Africa (1)
Francisco E. Estevez-Carrizo, MD (2) · Susana Parrillo, M.D. (2) · Walter Cacciavillano, MD (2) · Daniel Benisek, MD (1) · Dra. Ruth Weinberg (1) · Eduardo Spitzer, MSc (1) · Enrique Roca, MD (1) · Francisco Azzato, MD (1) · Gabriela Cinat, MD (1) · Guillermo Chantada, MD (1) · Guillermo Di Girolamo, MD (1) · Mariana Colonna, Bioch (1) · Mariano Duarte, MD (1) · Marina Sanchez Abraham, Neurologa (1)
PMID 26154941, PMID 26306290, PMID 30262136, PMID 32166534, PMID 32356926, PMID 33093900, PMID 34189446, PMID 34189447, PMID 41027700, PMID 42136000